Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 179 for your search:
Drug:
prednisone
Find trials that include:
Any drugs shown
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Prevention of Cyclophosphamide, Hydroxydaunorubicin (Adriamycin), Oncovin (Vincristine), Prednisone/Prednisolone (CHOP)-Induced Chronic Cardiotoxicity
Phase:
Phase IV
Type:
Supportive care, Treatment
Status:
Active
Age:
15 to 70
Sponsor:
Other
Protocol IDs:
OLSG-0401
, NCT00162955
2.
Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old.
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
15 to 60
Sponsor:
Other
Protocol IDs:
Hemato INCAN 01/2007
, NCT00429065
3.
Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV)
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
18 to 70
Sponsor:
Other
Protocol IDs:
2006-003750-23
, LINFOTARGAM, NCT00466258
4.
LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
65 and under
Sponsor:
Other
Protocol IDs:
LAL-Ph-2000
, NCT00526305
5.
Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
TaCyDexVMP7
, NCT00652041
6.
Treatment of High Risk Adult Acute Lymphoblastic Leukemia
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
16 and over
Sponsor:
Other
Protocol IDs:
LAL-AR/2003
, NCT00853008
7.
Thalidomide/Dexamethasone Vs MP for Induction Therapy and Thalidomide/Intron A Vs Intron A for Maintenance Therapy
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
19 and over
Sponsor:
Other
Protocol IDs:
01-002-0601
, NCT00205751
8.
Phase III Study of Early High-Dose Chemoradiotherapy and Autologous Peripheral Blood Stem Cell Transplantation Versus Conventional Dose Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients with Intermediate- or High-Grade Non-Hodgkin's Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
15 to 65
Sponsor:
NCI
Protocol IDs:
SWOG-S9704
, CAN-NCIC-LY11, CALGB-59903, ECOG-S9704, S9704, NCT00004031, LY11
9.
Phase III Randomized Study of Consolidation Therapy With or Without Strontium Chloride Sr 89 After Induction Chemotherapy in Patients With Androgen-Independent Prostate Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Any age
Sponsor:
NCI
Protocol IDs:
MDA-ID-00156
, NCI-3410, 3410, NCT00024167
10.
Phase III Randomized Study of Response-Based Chemotherapy With Doxorubicin, Bleomycin, Vincristine, Etoposide, Prednisone, and Cyclophosphamide With or Without Dexamethasone, Etoposide, Cytarabine, Cisplatin, and/or Radiotherapy in Children With Newly Diagnosed Intermediate-Risk Hodgkin's Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
21 and under
Sponsor:
NCI
Protocol IDs:
COG-AHOD0031
, NCT00025259, AHOD0031
11.
Phase III Randomized Study of Cyclophosphamide and Prednisone With or Without Immune Globulin in Pediatric Patients With Neuroblastoma-Associated Opsoclonus-Myoclonus-Ataxia Syndrome
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
8 and under
Sponsor:
NCI
Protocol IDs:
COG-ANBL00P3
, ANBL00P3, NCT00033293
12.
Phase III Randomized Study of Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, and Prednisone (BEACOPP) Versus Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) in Patients With Stage III or IV Hodgkin's Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
16 to 60
Sponsor:
Other
Protocol IDs:
EORTC-20012
, GELA-EORTC-20012, BNLI-EORTC-20012, GELCAB-EORTC-20012, NORDICLG-EORTC-20012, CAN-NCIC-EORTC-20012, ALLG-HD04, hd8, NCT00049595
13.
Phase III Randomized Study of Thalidomide and Prednisone as Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Multiple Myeloma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
16 and over
Sponsor:
NCI, Other
Protocol IDs:
CAN-NCIC-MY10
, NCT00049673, NCIC-MY.10, CAN-NCIC-JMY10, ECOG-NCIC-JMY10, MY10
14.
Phase III Randomized Study of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With Versus Without Rituximab in Elderly Patients With Aggressive Non-Hodgkin's Lymphoma (Randomized portion of the study completed as of 6/2005)
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
61 to 80
Sponsor:
Other
Protocol IDs:
DSHNHL-1999-1A
, EU-20243, NCT00052936
15.
Phase III Randomized Study of Dexamethasone Versus Prednisone During Induction and High-Dose Methotrexate With Leucovorin Rescue Versus Escalating-Dose Methotrexate Without Leucovorin Rescue During Interim Maintenance I in Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
1 to under 31
Sponsor:
NCI
Protocol IDs:
COG-AALL0232
, NCT00075725, AALL0232
16.
Phase III Randomized Study of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) Versus Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin and Rituximab (EPOCH-R) in Patients With Previously Untreated De Novo Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
CALGB-50303
, ECOG-50303, NCI-05-C-0252, NCT00118209
17.
Phase III Randomized Study of Docetaxel and Prednisone With Versus Without Atrasentan in Patients With Hormone-Refractory Stage IV Prostate Cancer and Bone Metastases
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
SWOG-S0421
, S0421, NCT00134056
18.
Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
30 and over
Sponsor:
Other
Protocol IDs:
05-043
, NCT00116142
19.
Phase III Randomized Study of Two Different Schedules of Docetaxel in Combination With Prednisone in Patients With Hormone-Refractory Metastatic Prostate Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Over 18
Sponsor:
Other
Protocol IDs:
AVENTIS-FIN-1-2003
, FINNISH-URO-OGS-1-2003, PROSTY-FIN-1-2003, NCT00255606
20.
Mega-CHOEP: Conventional Chemo Vs HD Chemo Followed by Auto SCT in Younger Pts With Aggressive Non-Hodgkin's Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 60
Sponsor:
Other
Protocol IDs:
DSHNHL 2002-1
, NCT00129090
21.
R-CHOP-14 Versus R-CHOP-21 and Darbepoetin Alpha in Patients Aged 60-80 Years With Diffuse Large B-Cell Lymphoma
Phase:
Phase III
Type:
Supportive care, Treatment
Status:
Active
Age:
66 to 80
Sponsor:
Other
Protocol IDs:
LNH03-6B
, NCT00144755
22.
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
553
, NCT00132301
23.
Rituximab After Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in Mantle Cell Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
60 and over
Sponsor:
Other
Protocol IDs:
MCL2004-1
, NCT00209209
24.
Efficacy of Rituximab - Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) Versus R-CHOP/R-DHAP in Patients With Untreated Mantle Cell Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 65
Sponsor:
Other
Protocol IDs:
MCL2004-2
, NCT00209222
25.
Phase III Randomized Study of Standard Chemoradiotherapy With Versus Without High-Dose Methotrexate in Pediatric Patients With Newly Diagnosed, Malignant High-Grade Glioma or Diffuse Intrinsic Pontine Glioma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
3 to 18
Sponsor:
Other
Protocol IDs:
GPOH-HIT-GBM-D
, EU-205100, NCT00278278
Select All on Page
1
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
